BG 1807
Alternative Names: BG-1807Latest Information Update: 03 Sep 2021
Price :
$50 *
At a glance
- Originator Guangzhou Bio-gene Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Gastric cancer; Oesophageal cancer
Most Recent Events
- 03 Sep 2021 BG 1807 is available for licensing as of 03 Sep 2021. https://www.gzbiogene.com/index.php/Technology/index
- 31 Aug 2021 Early research in Gastric cancer in China (Parenteral) (Guangzhou Bio-gene Technology pipeline, August 2021)
- 31 Aug 2021 Early research in Oesophageal cancer in China (Parenteral) (Guangzhou Bio-gene Technology pipeline, August 2021)